Product Images Gemfibrozil

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Gemfibrozil NDC 55700-493 by Lake Erie Medical Dba Quality Care Products Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

image description - New Doc 2017 02 14

image description - New Doc 2017 02 14

This is a warning and information label for a medication called G EM FIBROZ'L 600 MG. The medication contains Gemfibrozil, and the label provides information on dosage and storage instructions. It also indicates that the medication is only available by prescription and should be kept out of children's reach. The label includes a GTIN number (00355700493905), NDC number (55700-0493-90), lot number, expiration date, and serial number. The manufacturer is listed as InvaGen Pharmaceuticals, Inc. and the medication is in the form of a white, bisected capsule with the marking "G 225."*

image - b1f01502 634b 461a 8985 b639d190c9ef 01

image - b1f01502 634b 461a 8985 b639d190c9ef 01

image - b1f01502 634b 461a 8985 b639d190c9ef 02

image - b1f01502 634b 461a 8985 b639d190c9ef 02

This document presents a table showing the reduction in coronary heart disease rates in patients with different baseline lipid levels in the Helsinki Heart Study over a 52-year period. The table shows the incidence of events in terms of events per 1000 patients over five years. The table also mentions the use of gemfibrozil tablets and placebo groups to investigate the difference in rates between the two groups. The lipid values are presented in m/dL at baseline.*

image - b1f01502 634b 461a 8985 b639d190c9ef 03

image - b1f01502 634b 461a 8985 b639d190c9ef 03

This is a statistical table reporting the number of cardiac events and all-cause mortality per 1000 patients in different treatment groups during a 3.5 year follow-up study called the Helsinki Heart Study. The groups are labeled as PDrop, PN, PG, GDrop, GN, and GG, based on their original randomization and whether or not they attended clinics and took medication during the open-label follow-up period. The table shows the number of events and mortality rates for each group, with N representing the total number of patients in each group.*

image - b1f01502 634b 461a 8985 b639d190c9ef 04

image - b1f01502 634b 461a 8985 b639d190c9ef 04

This is a table from the Helsinki Heart Study showing the results of Cardiac events, Cardiac deaths, Non-cardiac deaths, and all-cause mortality for a group on Gemfibrozil and Placebo over an 8.5 year period. The table also gives the hazard ratio of Gemfibrozil to Placebo for each event. The analysis was an intention-to-treat analysis and neglected open-label treatment switches and exposure to study conditions. The text is readable.*

image - b1f01502 634b 461a 8985 b639d190c9ef 05

image - b1f01502 634b 461a 8985 b639d190c9ef 05

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.